Tacrolimus
B-Cell Acute Lymphoblastic Leukemia
Explore 136 assets in B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03856216CT.gov Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | — | Terminated | — | — | — |
NCT01256398CT.gov Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00792948CT.gov Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tacrolimus (this asset) | M.D. Anderson Cancer Center | P2 | B · 57 |
| Etoposide | University of Washington | P3 | BBB |
| Crisantaspase | City of Hope Medical Center | P3 | BB |
| Vincristine Sulfate | City of Hope Medical Center | P3 | BB |
| Dasatinib | National Cancer Institute (NCI) | P3 | BB |
| Nivestim | University of Washington | P3 | BB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Asparaginase | University of Washington | P3 | BB |
+42 more in the B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Tacrolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Transplantation | — | P4 | BBB · 79 |
| Disease Related To Solid Organ Transplantation | — | P4 | BBB · 76 |
| Beta-Thalassemia Major | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tacrolimus in B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tacrolimus-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →